Furthermore, the tremendous variability in tumor-associated p53 mutations and in expression levels of distinct p53-interacting proteins and p53 splice and promoter variants as well as p53-related proteins p63 and p73 could significantly affect the outcome of small molecule treatments. The gene discussed is TP53; the disease is neoplasm.